← Back to Search

Histone Deacetylase Inhibitor

1 for Leukemia

Phase 1
Waitlist Available
Research Sponsored by Mirati Therapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

In this study, MGCD0103, a new anticancer drug under investigation, is given twice weekly to patients with leukemia or myelodysplastic syndromes.

Eligible Conditions
  • Leukemia
  • Myelodysplastic Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2016 Phase 2 trial • 20 Patients • NCT02303262
60%
Fatigue
40%
Anemia
40%
Nausea
40%
Neutrophil count decreased
30%
Platelet count decreased
30%
Dyspnea
30%
Anorexia
25%
Vomiting
20%
Insomnia
20%
Diarrhea
20%
Dysgeusia
20%
White blood cell decreased
15%
Constipation
10%
Hypoalbuminemia
10%
Hypertension
10%
Dizziness
10%
Lymphocyte count decreased
10%
Chills
10%
Decreased appetite
10%
Pain
10%
Dry mouth
10%
Hypokalemia
10%
Acid reflux
10%
Alkaline phosphatase increased
10%
Back pain
10%
Dehydration
10%
Headache
10%
Fever
5%
Bruising
5%
Thigh pain
5%
Pericarditis
5%
GGT increased
5%
Sciatic pain
5%
Muscle cramps
5%
Neck stiffness
5%
Pericardial tamponade
5%
Fracture
5%
Laryngeal inflammation
5%
Peripheral sensory neuropathy
5%
Facial acne
5%
Fungal infection
5%
Right sided chest pain
5%
Hypotension
5%
Myalgia
5%
Absolute neutrophil count decreased
5%
Night sweats
5%
Palpitations
5%
Hypocalcemia
5%
Hyponatremia
5%
Sore nostril
5%
Malaise
5%
Arthralgia
5%
Ejection fraction decreased
5%
Nasal irritation
5%
Neck pain
5%
Paresthesia
5%
Pruritic rash
5%
Calf tenderness/burning
5%
Memory impairment
5%
Powerport soreness
5%
Hydronephrosis
5%
Pulmonary embolism
5%
Cord compression
5%
Pharyngitis
5%
QTCF elevated
5%
Achy
5%
Alanine Aminotransferase increased
5%
Cough
5%
Creatinine increased
5%
Erythematous neck rash
5%
Flatulence
5%
Hypophosphatemia
5%
Burping
5%
Dry skin
5%
Elevated LFTs
5%
Generalized muscle weakness
5%
Weight loss
5%
Bronchopulmonary hemorrhage
5%
Failure to thrive
5%
Febrile neutropenia
5%
Mucositis
5%
Neutropenia
5%
Non-cardiac chest pain
5%
Pericardial effusion
5%
Pneumonia
5%
Syncope
5%
Upper respiratory infection
5%
Urinary tract infection
5%
Sharp left sided pain
5%
Shoulder pain
5%
Sore throat
5%
Stomatitis
5%
Throat irritation
5%
Thrush
5%
Ventricular arrhythmia
5%
Vertigo
5%
Voice alteration
100%
80%
60%
40%
20%
0%
Study treatment Arm
Mocetinostat and Gemcitabine

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention
MGCD0103 oral dose 2 times per week.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mocetinostat
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Mirati Therapeutics Inc.Lead Sponsor
70 Previous Clinical Trials
8,104 Total Patients Enrolled
5 Trials studying Leukemia
157 Patients Enrolled for Leukemia
Gregory Reid, MSc, MBAStudy DirectorMethylGene Inc.
12 Previous Clinical Trials
668 Total Patients Enrolled
5 Trials studying Leukemia
157 Patients Enrolled for Leukemia
~1 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top